Cargando…
HJC0152, a novel STAT3 inhibitor with promising anti-tumor effect in gastric cancer
BACKGROUND: Aberrant activation of the signal transducer and activator of transcription 3 (STAT3) is frequently seen in patients with gastric cancer (GC), and is generally associated with worse prognosis. HJC0152, a novel STAT3 inhibitor, has shown significant anti-tumor effects in several cancers,...
| Autores principales: | , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Dove Medical Press
2018
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6296682/ https://www.ncbi.nlm.nih.gov/pubmed/30588091 http://dx.doi.org/10.2147/CMAR.S188364 |